Why 2026 Is the Pivotal Year for Bispecific & Multispecific Development in Europe
After years of steady growth, the bispecific field has entered a new era of acceleration. Investment is increasing, clinical activity is expanding, and engineering breakthroughs are reshaping what’s possible across oncology, immunology, and autoimmune diseases. With experts projecting the global bispecific market to reach $163 billion by 2032, momentum is building at a pace the industry has never seen.
Amid this surge, developers face a new set of questions:
- How do we design for manufacturability and differentiation?
- How do we expand the therapeutic window without sacrificing potency?
- How can teams better predict safety, toxicity, and translational risk?
These challenges have created the perfect moment to launch the World Bispecific Summit Europe, a new forum dedicated to helping European drug developers navigate the opportunities and challenges defining bispecifics in 2026 and beyond.
Why Bispecific Matters More Than Ever
The last 12 months have delivered a wave of headline‑defining advancements that illustrate just how fast the space is evolving:
Bispecifics Move Beyond Oncology:
UCB’s $1.1B push into autoimmune T‑cell engagers signals a pivotal shift. With companies like Sanofi, Immunocore, AstraZeneca, and T‑Cypher Bio expanding into immunology and autoimmunity, developers are now redefining target selection and risk management strategies for non‑oncology indications.
Multispecifics Gain Commercial Momentum:
Partnerships such as Earendil Labs × WuXi Biologics show how multispecifics are moving from technical exploration to mainstream pipeline strategy. Developers like Pfizer, Zymeworks, and DISCO are actively investing in multi‑arm and multi‑functional modalities that will shape the next generation of precision therapies.
Next‑Gen Formats Enter the Clinic
The recent clinical entry of Alphamab’s dual‑payload EGFR/HER3 bispecific ADC showcases the industry’s appetite for advanced engineered designs, conditional activation systems, and innovative payload strategies.
Regulatory Engagement and Clinical Expectations Are Rising
What to Expect in 2026
The inaugural agenda features more than 25 expert speakers, including 14 presenting brand‑new data.
Attendees will gain access to insights that span the entire development process, including:
Benchmarking Emerging Engineering Approaches
Strengthening the Therapeutic Window
Understand practical methods for optimising potency, enhancing selectivity, and reducing toxicity through improved engineering and translational design.
Hands-On Workshops on Collaborative Project Delivery
Hear directly from teams advancing programmes across oncology, autoimmunity, and immunology to uncover best practices and avoid common pitfalls.
Building Strategic Partnerships
Why This Launch Matters
Europe’s multispecific ecosystem is growing rapidly, but it has lacked a single, industry‑focused platform dedicated to the unique scientific, operational, and translational challenges of bispecific development. The launch of the World Bispecific Summit Europe fills this gap at exactly the right moment.
With accelerating pipelines, increasing investment, and rising scientific complexity, 2026 represents a critical year for teams looking to advance next‑generation bispecific and multispecific therapeutics confidently toward the clinic.
Explore the Full Event Guide
- Hear from 25+ world-class speakers across pharma and biotech sharing cutting-edge data on bispecific antibodies, T-cell engagers, and next-generation multispecific formats advancing toward clinical success
- Connect with 60+ senior attendees driving innovation in solid tumour targeting, immune cell redirection, and next-generation engineering strategies
- Gain insights from 20+ data-driven presentations covering translational challenges, safety optimisation, potency enhancement and strategies to improve clinical durability
- Take part in a dedicated Scientific Poster Session, spotlighting novel targets, platform technologies, and preclinical-to-clinical translation data
- Unlock 7+ hours of high-value networking, designed to foster strategic collaborations, partnerships, and pipeline acceleration
